Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose IL-2 for Behçet's Syndrome
NCT04065672Phase 2Completed
- Sponsor
- Hejing Biotechnology
- Start
- Oct 2021
- Primary completion
- Apr 2023
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in Behçet's disease (BD), sponsored by Hejing Biotechnology. Started Oct 2021; status: completed.
02
Drugs
aldesleukin
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on NCT04065672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04065672.